Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Rapalogs (everolimus, temsirolimus) inhibit mTOR signaling and are used as antiproliferative cancer drugs.
• The impact of rapalog-mediated immune modulation on their antitumor efficacy requires further investigation.

Purpose of the Study:

• To investigate how rapalogs influence the immune system and affect their own antitumor efficacy.
• To explore the dual role of adaptive T-cell immunity in response to rapalog therapy.

Main Methods:

• Analysis of regulatory T cells (Tregs) and Th1 cells in metastatic renal cell carcinoma patients treated with everolimus.
• In vivo studies using tumor-bearing mice to confirm the effects of rapalog-induced Tregs.
• Combination therapy evaluation with temsirolimus and a CCR4 antagonist.

Main Results:

• Everolimus treatment increased the expansion and suppressive function of regulatory T cells (Tregs).
• A concurrent activation of tumor-specific Th1 immunity and increased Eomes(+)CD8(+) T cells were observed.
• Patients with decreased Tregs and increased Th1 cells showed better clinical responses.
• Rapalog-induced Tregs were found to inhibit antitumor T-cell immunity in mice.
• Combination therapy with temsirolimus and a CCR4 antagonist demonstrated superior efficacy compared to monotherapy.

Conclusions:

• Rapalogs have a dual impact on host adaptive antitumor T-cell immunity, affecting clinical effectiveness.
• The balance between Tregs and antitumor Th1 cells influences treatment outcomes.
• Combining rapalogs with immunotherapies, such as CCR4 antagonists, may enhance antitumor efficacy.